Last reviewed · How we verify
NCT04517630
Renal Biomarkers in AKI and COVID-19
trial testing urinary NGAL, TIMP-2, IGFBP7, IL-6, viral load and metabolomic in Coronavirus Infection in 51 participants. Completed in 30 September 2021.
30 September 2020
Quick facts
| Lead sponsor | Instituto Nacional de Enfermedades Respiratorias |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 51 |
| Start date | 1 June 2020 |
| Primary completion | 30 September 2020 |
| Estimated completion | 30 September 2021 |
| Sites | 1 location across Mexico |
Drugs / interventions tested
- urinary NGAL, TIMP-2, IGFBP7, IL-6, viral load and metabolomic
Conditions studied
- Coronavirus Infection — all drugs for Coronavirus Infection →
- Covid19 — all drugs for Covid19 →
- SARS (Severe Acute Respiratory Syndrome) — all drugs for SARS (Severe Acute Respiratory Syndrome) →
- AKI — all drugs for AKI →
Sponsor
Instituto Nacional de Enfermedades Respiratorias — full company profile →
Who can join
Adults 18 to 70, any sex, with Coronavirus Infection or Covid19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Severe pneumoniae related to Coronavirus Disease (COVID-19), had a high in-hospital mortality; this condition are worst in subjects with acute kidney disease (AKI); conditioning increased mortality, days of assisted mechanical ventilation (AMV), increased nosocomial infections and high costs. We need many studies for determinated the risk factors for AKI in subjects with COVID-19. This study pretends identify the incidence of AKI in subjects with severe pneumoniae by COVID-19, describe the role of some biomarkers in the physiopathology of AKI-COVID-19; and determine the evolution of urinary biomarkers during hospitalization, like neutrophil gelatinase-associated lipocalin (NGAL), tissue inhibitor of metalloproteinases-2 (TIMP-2), insulin-like growth factor binding protein-7 (IGFBP7), and interleukin-6 (IL-6) and the progression of viruria of Severe Acute Respiratory Syndrome (SARS) related to CoronaVirus 2 (CoV2) in subjects with or without AKI.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04517630
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Coronavirus Infection
Currently open trials in the same condition.
- NCT04885504 — Post COVID-19 Biorepository · recruiting
- NCT04445454 — Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection · Phase 1, PHASE2 · recruiting
- NCT04510025 — Capturing MultiORgan Effects of COVID-19 · recruiting
- NCT04376034 — Convalescent Plasma Collection and Treatment in Pediatrics and Adults · Phase 3 · recruiting
Other Instituto Nacional de Enfermedades Respiratorias trials
Trials by the same sponsor.
- NCT06471101 — Applying Artificial Intelligence to Identify Subphenotypes of Acute Kidney Injury in Mexican Patients With Severe COVID- · completed
- NCT06691321 — Caspofungin for Pneumocystis Pneumonia in PLWHIV. · recruiting
- NCT04443673 — Glycine Supplement for Severe COVID-19 · NA · terminated
- NCT06444893 — Morphofunctional, Gene, Inflammation Molecules and Oxidative Stress Analysis in Kidney Tissue of COVID-19 Patients · completed
- NCT03627481 — Sleep Quality After Nasosinusal Surgery in AERD Patients · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04517630 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Instituto Nacional de Enfermedades Respiratorias
- Last refreshed: 6 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04517630.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing